

OA Product & Service Agreements

Oncology Associates offers a diverse portfolio of major pharmaceutical manufacturers' products at favorable prices to our members. In addition, OA offers several practice management services. Please see the list below for descriptions and contact information for our manufacturer and service agreements.

Amgen

800.447.1000

Products: Aranesp, Neulasta, Neupogen

Aspen Consulting Group LTD

877.238.7032

Specializes in the independent assessment of healthcare practice **internal controls, operations and management**

Aventis

800.996.6626

(Reimbursement Hotline)

Products: Anzemet, Taxotere

Bedford Labs

800.562.4797

Offers an entire suite of **generic drugs** including but not limited to:

Cisplatin, Cladribine, Doxorubicin, Leucovorin, Paclitaxel, Pamidronate

GlaxoSmithKline

888.825.5249

Products: Hycamtin, Navelbine, Zofran

Medical Specialties

800.967.6400

Rental of oncology infusion pumps

MedImmune Oncology, Inc.

877.633.4411

Product: Ethyol

MDinTouch

866.774.0002

Web-based **dictation and transcription**

MGI Pharma, Inc.

866.302.5694

(Reimbursement Hotline)

Product: Aloxi

Novartis Oncology

877.527.4357

Product: Sandostatin LAR

Novidea Healthcare

877.503.1455

Professional Employer Organization for healthcare providers.

Ortho Biotech

800.325.7504

Product: Procrit

Pharmion

720.564.9100

Products: Innohep, Vidaza

Roche, Inc.

973.235.5000

Product: Kytril

SICOR

800.729.9991

Products: Aducril, Carboplatin Injection, Carboplatin for Injection, Fludarabine, Fludarabine Phosphate Injection, IDArubicin Injection, Ifosfamide/Mesna Kit, Leuprolide Acetate, Mesna Injection, Vinorelbine Tartrate Injection

Wyeth/Genetics Institute

617.876.1170

Product: Neumega



New Agent, Vidaza, added to the Pharmion Agreement

We are pleased to announce the launch of Vidaza (azacitidine for injectable suspension) and its addition to the Pharmion agreement. This product will become available to all OA Members in good standing July 1, 2004.

Vidaza is available in 100 mg vials and is indicated for the treatment of all five Myelodysplastic Syndrome (MDS) subtypes. These subtypes include:

- > Refractory anemia (RA)
- > Refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions)
- > Refractory anemia with excess blasts (RAEB)
- > Refractory anemia with excess blasts in transformation (RAEB-T)
- > Chronic myelomonocytic leukemia (CMML)

MDS is a group of diseases characterized by failure of the bone marrow to produce enough normal blood cells. In about one-third of patients, the disease transforms into acute leukemia. For this reason, MDS is sometimes referred to as "pre-leukemia" or "smoldering leukemia".

For more information on Vidaza, visit Pharmion's web site at pharmion.com or contact Pharmion directly for complete prescribing information at **1-866-PHARMION**. Please call Oncology Associates at **888-732-7352** with any questions regarding this agreement.

Product	Package	
	Size	NDC#
Vidaza	100 mg/vial	67211-102-01
(azacitidine for injectable suspension)		